News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
ORBIMED ADVISORS LLC
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 8.2% stake in X4 PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in VistaGen Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 10.7% stake in VectivBio Holding AG |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Theravance Biopharma, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Sonendo, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 9.3% stake in SI-BONE, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 3.3% stake in RxSight, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 6% stake in Protara Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 16.1% stake in NeuroPace, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 5.9% stake in Crinetics Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Catalyst Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 10% stake in Applied Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 2.9% stake in Aeglea BioTherapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 1.2% stake in Xenon Pharmaceuticals Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 6.4% stake in X4 PHARMACEUTICALS, INC. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Verrica Pharmaceuticals Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 7.4% stake in Theravance Biopharma, Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Strongbridge Biopharma plc |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 16.5% stake in NeuroPace, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 8.1% stake in MeiraGTx Holdings plc |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 5.1% stake in Harpoon Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 4.5% stake in Fluidigm Corporation |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 6.7% stake in Crinetics Pharmaceuticals Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 8% stake in Applied Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 7.9% stake in Aeglea BioTherapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/06/2021 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 4% stake in CTI BioPharma Corp. |
| 10/14/2021 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Kala Pharmaceuticals Inc. |
|
|
|